Thanks @Moreforme ... who would have thought the FDA approving a drug that didn't meet its PE; the FDA even encouraged the application from Novartis .... makes for interesting conversations with MSB and the FDA about Rexlemestrocel-L (REVASCOR®especially if Novartis partner with MSB for CHF as well as ARDS
The agency primarily based its review on results from Novartis’ Phase III PARAGON-HF study, which, unlike most other successful pivotal trials, didn’t actually hit its primary endpoint of reducing the rate of total heart failures and death. Despite the flop, the FDA urged Novartis to pursue its application anyway, arguing the study’s design may have produced misleading results — the primary endpoint’s p-value was 0.06, by the way — and highlighting results from pre-specified follow-up analyses that pointed to significant benefits.
- Forums
- ASX - By Stock
- MSB
- Novartis - Heart Failure - Primary Endpoints
Novartis - Heart Failure - Primary Endpoints, page-3
-
- There are more pages in this discussion • 98 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.07 |
Change
0.005(0.47%) |
Mkt cap ! $1.216B |
Open | High | Low | Value | Volume |
$1.08 | $1.10 | $1.06 | $3.371M | 3.135M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 45345 | $1.06 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.07 | 3875 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
8 | 45345 | 1.055 |
9 | 193430 | 1.050 |
3 | 44331 | 1.045 |
5 | 117942 | 1.040 |
3 | 53830 | 1.035 |
Price($) | Vol. | No. |
---|---|---|
1.065 | 3875 | 2 |
1.070 | 28953 | 3 |
1.075 | 46564 | 3 |
1.080 | 87551 | 5 |
1.085 | 47614 | 4 |
Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |